Clinical Effect of Bifidobacterium Triple Viable Bacteria Combined with Cetirizine in the Treatment of Eczema in Children and its Effect on Immunoglobulin Levels

Objective: To analyze the clinical effect of Bifidobacterium triple viable bacteria combined with cetirizine in the treatment of eczema in children and its impact on the immunoglobulin levels of the children. Methods: 50 children with eczema who received treatment in our hospital from January 2021 to December 2022 were selected as research subjects and divided into 25 cases in a group using the computer randomization method. In addition to basic treatment for both groups, patients in the control group were treated with cetirizine, while the observation group was treated with Bifidobacterium triple viable bacteria and cetirizine. The immunoglobulin levels, inflammatory factor levels, intestinal flora numbers, treatment effects, and recurrence rates within six months were compared between the two groups before and after treatment. Results: Before treatment, there was little difference in the indicators between the two groups of children (P> 0.05). After treatment, various immunoglobulins (IgM and IgG), inflammatory factors (interleukin-4 and interleukin-10), and the number of intestinal flora (including Escherichia coli, Lactobacillus, and Bifidobacterium) in the observation group was better than that of the control group, the total effective rate of treatment was higher than that of the control group, and the recurrence rate within six months was lower than that of the control group (P < 0.05). Conclusion: Bifidobacterium triple viable bacteria combined with cetirizine can actively regulate immunoglobulin levels and the number of intestinal flora, control inflammatory reactions, and have high treatment effectiveness and low recurrence rates in the treatment of pediatric eczema.